Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

IncobotulinumtoxinA

Aliases
Botulinum toxin type A (150 kiloDalton), free from complexing proteins, NT 201, Xeomin
Name
Xeomin
INN Name
incobotulinumtoxinA
FDA Approved
Yes

6 clinical trials

2 organizations

7 indications

1 document

Indication
Chronic Peripheral Neuropathic Pain Due to Postherpetic Neuralgia or Peripheral Nerve Injury
Indication
N/A
Indication
No Specific Medical Condition Will be Treated
Indication
Glabellar Frown Lines
Indication
Migraine
Indication
Overactive Bladder
Indication
Cosmetic Techniques
Clinical trial
A Parallel-group Treatment, Proof-of-concept Phase 2, Multicenter, Double-blind, Randomized Two-arm Clinical Trial to Investigate the Efficacy and Safety of Subcutaneous NT 201 Injections Compared With Placebo Injections in Decreasing Pain Intensity in Male and Female Participants Aged 18 Years and Older With Moderate to Severe Chronic Peripheral Neuropathic Pain Due to Postherpetic Neuralgia or Peripheral Nerve Injury
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 1 Single-center Study to Evaluate the Distribution of NT 201 Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods
Status: Completed, Estimated PCD: 2023-02-24
Clinical trial
LONG RUN: LONGitudinal Evaluation and Real-world Evidence of Uniquely Purified incobotulinumtoxinA (Xeomin) in Treatment Naïve Participants
Status: Terminated, Estimated PCD: 2023-05-18
Clinical trial
Single Center Study on the Sustained Effect of OnabotulinumtoxinA (BOTOX®) vs. IncobotulinumtoxinA (XEOMIN®) Botulinum Toxin in Adults With Chronic Migraine
Status: Recruiting, Estimated PCD: 2025-02-24
Clinical trial
Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA Efficacy and Safety in Women With Overactive Bladder and Urge Urinary Incontinence and the Value of Local Anesthesia for Pain Reduction
Status: Completed, Estimated PCD: 2022-11-25
Clinical trial
A Randomized Prospective Evaluation of Four Injectable Neuromodulators in the Glabella Area
Status: Completed, Estimated PCD: 2023-06-30
Document
DailyMed Label: Xeomin
Organization
Merz North America, Inc.
Organization
Merz Pharmaceuticals, LLC